Sectors

INAB
IN8bio, Inc.
1.23
1 x 1.22
1 x 1.23
bid
ask
-
0.01
0.81%
10:57 AM
timesize
Ytd-47.44%
1y-48.10%
1.23
day range
1.25
1.17
52 week range
2.73
Open1.25Prev Close1.24Low1.23High1.25Mkt Cap11.89M
Vol7.45KAvg Vol58.13KEPS-2.61P/E-0.48Forward P/E-0.80
Beta0.22Short Ratio0.51Inst. Own46.46%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0750-d Avg1.48200-d Avg1.751yr Est4.75

INAB News

benzinga.com
IN8bio Announces Publication Of Peer-Reviewed Clinical Data From Phase 1 Trial Of INB-200 In The Jou

First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
globenewswire.com
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles P

First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant

12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

IN8bio (INAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
zacks.com
IN8bio (INAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for IN8bio (INAB), indicating

IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
globenewswire.com
IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell En

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmac

IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
globenewswire.com
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnos

Repeat dosing of DeltEx TM Drug Resistant Immunotherapy (DRI) had a median progression-free survival

IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026 Repor

IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
globenewswire.com
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day

NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) (“IN8bio” or the “Company”),

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical

Comparing XBiotech (NASDAQ:XBIT) & IN8bio (NASDAQ:INAB)
defenseworld.net
Comparing XBiotech (NASDAQ:XBIT) & IN8bio (NASDAQ:INAB)

IN8bio (NASDAQ: INAB - Get Free Report) and XBiotech (NASDAQ: XBIT - Get Free Report) are both small

IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026
globenewswire.com
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Imp

Presented updated glioblastoma (“GBM”) data demonstrating durable survival and a favorable safety pr

IN8bio to Present at TD Cowen 46th Annual Health Care Conference
globenewswire.com
IN8bio to Present at TD Cowen 46th Annual Health Care Conference

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmac

IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
globenewswire.com
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer

NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutica

IN8bio to Present at Upcoming Investor and Scientific Conferences in February
globenewswire.com
IN8bio to Present at Upcoming Investor and Scientific Conferences in February

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmac

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma
globenewswire.com
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements i

NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmac

IN8bio (NASDAQ:INAB) & Cadrenal Therapeutics (NASDAQ:CVKD) Head to Head Review
defenseworld.net
IN8bio (NASDAQ:INAB) & Cadrenal Therapeutics (NASDAQ:CVKD) Head to Head Review

IN8bio (NASDAQ: INAB - Get Free Report) and Cadrenal Therapeutics (NASDAQ: CVKD - Get Free Report) a

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
globenewswire.com
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T

$20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio's

benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights
globenewswire.com
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrat

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
globenewswire.com
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmac

IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
globenewswire.com
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications

INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compo

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
globenewswire.com
IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progressio

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
globenewswire.com
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblasto

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmac

benzinga.com
Stocks That Hit 52-Week Lows On Friday

  On Friday morning, 446 companies hit new 52-week lows.

benzinga.com
Why This Healthcare Stock Dipped Over 75%; Here Are 73 Biggest Movers From Yesterday

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares climbed 53.2% to close at $3.14 on Wednes